Baker Tilly Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $672K | Buy |
1,280
+125
| +11% | +$65.6K | 0.24% | 95 |
|
|
2025
Q1 | $733K | Buy |
1,155
+641
| +125% | +$407K | 0.29% | 90 |
|
|
2024
Q4 | $366K | Sell |
514
-222
| -30% | -$158K | 0.14% | 160 |
|
|
2024
Q3 | $774K | Buy |
736
+137
| +23% | +$144K | 0.34% | 72 |
|
|
2024
Q2 | $630K | Sell |
599
-432
| -42% | -$454K | 0.26% | 94 |
|
|
2024
Q1 | $992K | Buy |
1,031
+3
| +0.3% | +$2.89K | 0.18% | 125 |
|
|
2023
Q4 | $903K | Sell |
1,028
-243
| -19% | -$213K | 0.15% | 147 |
|
|
2023
Q3 | $1.05M | Sell |
1,271
-2,338
| -65% | -$1.92M | 0.17% | 124 |
|
|
2023
Q2 | $2.59M | Buy |
3,609
+77
| +2% | +$55.3K | 0.27% | 82 |
|
|
2023
Q1 | $2.9M | Buy |
3,532
+183
| +5% | +$150K | 0.33% | 67 |
|
|
2022
Q4 | $2.42M | Sell |
3,349
-84
| -2% | -$60.6K | 0.3% | 77 |
|
|
2022
Q3 | $2.37M | Buy |
3,433
+222
| +7% | +$153K | 0.32% | 71 |
|
|
2022
Q2 | $1.9M | Sell |
3,211
-437
| -12% | -$258K | 0.25% | 86 |
|
|
2022
Q1 | $2.55M | Buy |
3,648
+537
| +17% | +$375K | 0.28% | 75 |
|
|
2021
Q4 | $1.97M | Buy |
3,111
+435
| +16% | +$275K | 0.21% | 95 |
|
|
2021
Q3 | $1.62M | Buy |
2,676
+552
| +26% | +$334K | 0.21% | 93 |
|
|
2021
Q2 | $1.19M | Buy |
2,124
+200
| +10% | +$112K | 0.19% | 117 |
|
|
2021
Q1 | $910K | Sell |
1,924
-208
| -10% | -$98.4K | 0.19% | 131 |
|
|
2020
Q4 | $1.03M | Buy |
+2,132
| New | +$1.03M | 0.32% | 77 |
|